Fig. 6
From: The synergism of SMC1A cohesin gene silencing and bevacizumab against colorectal cancer
SMC1A and colorectal cancer. The overexpression of SMC1A reduced the latency period of cancer formation in a subcutaneous murine xenograft model and the volume of tumors were significantly increased in presence of upregulated SMC1A. The subsequent shRNA-mediated SMC1A silencing effectively downregulated cancer progression and this effect was enhanced following the combined treatment, shRNA against SMC1A plus bevacizumab